Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation (NASDAQ: BCPC) is a global specialty ingredient manufacturer for health and nutrition markets, and its news flow reflects this focus. Company press releases highlight the development, manufacture and marketing of specialty ingredients that improve and enhance the health and well-being of life on the planet, as well as financial and corporate updates relevant to investors and industry observers.
Visitors to this BCPC news page can review Balchem’s announcements on quarterly financial results, dividend declarations and participation in investor conferences. Recent releases have reported segment-level performance for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments, along with measures such as net sales, earnings from operations, adjusted EBITDA and free cash flow, as described in accompanying Form 8-K filings.
Balchem also issues news related to regulatory and trade developments that affect its markets. For example, the company joined another EU producer in welcoming European Union anti-dumping duties on choline chloride imports from China, emphasizing the importance of fair trade for the EU food and feed supply chain and for maintaining a healthy domestic choline chloride industry.
In addition, Balchem regularly announces its participation in conferences hosted by firms such as CJS Securities, Baird, H.C. Wainwright, Wells Fargo and others, where its leadership presents to the investment community. These updates provide insight into how the company communicates its strategy and segment performance to shareholders and analysts. Investors and researchers can use this news stream to follow Balchem’s financial reporting, capital allocation decisions such as dividends, and its commentary on market and regulatory conditions affecting its human nutrition, animal nutrition and specialty products businesses.
Balchem (NASDAQ: BCPC) will host a conference call on February 20, 2026 at 11:00 AM ET to review fourth quarter and full year 2025 results. Results and financial exhibits will be published prior to market open that day and posted on the company website.
The live webcast and replay will be available at the provided Q4 Events link; dial‑in details and Conference ID 4400943 are available for investors and analysts.
Balchem (NASDAQ: BCPC) will participate in the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026. Company representatives attending include Ted Harris (chairman, president and CEO), Martin Bengtsson (CFO) and Allison Baurichter (senior director, investor relations). The virtual presentation provides an opportunity for management to discuss strategy and engage with investors.
Balchem (NASDAQ:BCPC) and Eastman welcomed the EU decision published on Dec 19, 2025 to impose anti-dumping duties of 90.0%–115.9% on choline chloride imports from China, effective for five years with possible renewal.
The producers say the measures protect EU food and feed supply chains, preserve jobs, support continued EU investment and innovation, and ensure supply stability and high health and safety standards. The statement also notes revised customs origin rules clarifying that liquid choline chloride retains Chinese origin if the key chemical reaction occurred in China, helping prevent circumvention.
Balchem (NASDAQ: BCPC) announced that on Dec 9, 2025 its board declared an annual dividend of $0.96 per share, payable Jan 20, 2026 to holders of record at the close of business on Dec 23, 2025.
The dividend equals a 10.3% increase versus last year and marks the seventeenth consecutive annual dividend increase, which management links to sustained financial performance and board confidence in long-term strategy.
Balchem (NASDAQ: BCPC) will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025. Key speakers scheduled are Ted Harris (Chairman, President & CEO), Martin Bengtsson (CFO) and Allison Baurichter (Senior Director Investor Relations).
The presentation signals management engagement with investors at a major industry conference; no financial data, times, or webcast details were provided.
Balchem (NASDAQ: BCPC) reported third quarter fiscal 2025 results for the period ended September 30, 2025: net sales $267.6M (up 11.5% vs. prior year), net earnings $40.3M (up 19.1%), adjusted EBITDA $71.4M (up 11.0%), and free cash flow $50.7M. Cash from operations was $65.6M. Net debt was reduced to $88.9M with a leverage ratio of 0.3x. The Human Nutrition and Health segment reported record sales of $174.1M (up 14.3%).
Recent milestones include approvals to build a new microencapsulation facility in Orange County, NY, and five new sponsored research studies published in the quarter, including a choline biomarker study.
Balchem (NASDAQ: BCPC) will hold a conference call on Tuesday, October 21, 2025 at 11:00 AM ET to review third quarter 2025 results. The company said results and accompanying financial exhibits will be released prior to the market open on October 21, 2025.
Management presenters are Ted Harris, Chairman, President and CEO, and Martin Bengtsson, CFO. Institutional investors and analysts can join by dial-in numbers provided, and the public may listen via a live webcast at https://events.q4inc.com/attendee/857727932. A replay will be available at the same link for one year after the call.
Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer focused on health and nutrition markets, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 9, 2025.
The company will be represented by key executives including Ted Harris (Chairman, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director of Investor Relations).
Balchem Corporation (NASDAQ: BCPC) reported strong Q2 2025 financial results with record net sales of $255.5 million, up 9.1% year-over-year. The company achieved net earnings of $38.3 million, a 19.4% increase, and record adjusted EBITDA of $69.2 million, up 11.2%.
All three business segments showed growth, with Human Nutrition and Health achieving record sales of $160.8 million (up 8.7%), Animal Nutrition and Health reaching $56.0 million (up 13.1%), and Specialty Products posting record sales of $37.2 million (up 6.0%).
Key developments include plans for a new $36 million micro-encapsulation facility in Orange County, NY, and the European Commission's implementation of 95.4% to 120.8% anti-dumping duties on Chinese choline chloride imports.
Balchem Corporation (NASDAQ: BCPC) has scheduled its second quarter 2025 financial results conference call for July 31, 2025, at 11:00 AM Eastern Time. The company's Chairman, President and CEO Ted Harris, along with CFO Martin Bengtsson, will host the call.
The Q2 2025 results will be released before market opening on the same day and will be available on www.balchem.com. Institutional investors and analysts can join by dialing 800-715-9871 (USA/Canada toll-free). A live webcast and replay will be accessible at the company's investor events portal.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
